Head-to-head · Cost-Efficiency Index
Novi vs OrderlyMeds
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Novi
Shoppers drawn to the lowest flat headline price in this batch, if they're comfortable that dosing, coverage states, and pharmacy details aren't published anywhere on the site.
Visit NoviOrderlyMeds
Cost-first shoppers who want a first GLP-1 course at a published starter rate, with the standing rate published beside it.
Visit OrderlyMedsThe verdict
Novi takes it, leading the Cost-Efficiency Index 69 to 68. Novi is a compounded GLP-1 telehealth brand advertising semaglutide from $99/month and tirzepatide from $133/month — both framed as marked down from a $299 standing price and paired with a live countdown-timer urgency device. OrderlyMeds still earns a C — Cost-first shoppers who want a first GLP-1 course at a published starter rate, with the standing rate published beside it.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Novi.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Novi | OrderlyMeds |
|---|---|---|
| Cost-Efficiency Index | 69/100 | 68/100 |
| Semaglutide / mo | $99/mo (all doses, promotional rate, compounded) | $74/mo (starting dose, 2-mo starter plan, new patients only, compounded) |
| Tirzepatide / mo | $133/mo (all doses, promotional rate, compounded) | $299/mo (compounded) |
| Semaglutide / yr (modeled) | $1,188 | $888 |
| Tirzepatide / yr (modeled) | $1,596 | $3,588 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #105 | #112 |
Novi
69/100Where the value is
- Lowest advertised entry price in this entire batch for both drugs ($99 semaglutide / $133 tirzepatide)
- LegitScript certified, independently verifiable via the linked legitscript.com record
- States one flat price per dose with no separate visit fee and free shipping
The tradeoffs
- No published mg dose, supply duration, state-coverage list, named medical director, or named compounding pharmacy anywhere on the site or its help center — the least transparent operational disclosure of any company researched in this batch
- The advertised $99/$133 rate is displayed against a live countdown timer ('price increases in...') next to a claimed $299 original price, a scarcity tactic that makes it unclear whether this is a genuine standing rate or a recurring promotional one
OrderlyMeds
68/100Where the value is
- The starter rate and the standing rate are both published, so the step-up is visible before signing up
- No membership fees and no hidden costs, stated as such
- The dose ladder is published: four weeks at 0.25 mg then four weeks at 0.5 mg
The tradeoffs
- The $74 rate is a two-month starter plan billed as $149 up front, and it is open only to patients new to GLP-1 medication; the standing monthly rate is $149
- Tirzepatide has no equivalent standing discount — $299/mo is the ongoing rate
Regulatory note: the FDA issued a warning letter to OrderlyMeds LLC dba OrderlyMeds in June 2026. We still list and link to OrderlyMeds; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.